kabutan

ReproCELL Incorporated(4978) Summary

4978
TSE Growth
ReproCELL Incorporated
166
JPY
-10
(-5.68%)
Mar 13, 3:30 pm JST
1.04
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
166
Mar 13, 11:49 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.79
Yield
ー%
Margin Trading Ratio
Stock Price
Mar 13, 2026
Opening Mar 13, 9:03 am
168 JPY 1.05 USD
Previous Close Mar 12
176 JPY 1.10 USD
High Mar 13, 9:03 am
170 JPY 1.06 USD
Low Mar 13, 9:22 am
165 JPY 1.03 USD
Volume
1,412,600
Trading Value
0.24B JPY 1.48M USD
VWAP
167.25 JPY 1.05 USD
Minimum Trading Value
16,600 JPY 104 USD
Market Cap
0.02T JPY 0.10B USD
Number of Trades
515
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Slightly High
1-Year Average
701
1-Year High Jul 2, 2025
8,480
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 5,400 4,928,500 912.69
Feb 27, 2026 0 5,575,500
Feb 20, 2026 0 5,972,800
Feb 13, 2026 0 5,854,900
Feb 6, 2026 0 5,940,900
Company Profile
ReproCELL Incorporated is a biotech venture company specializing in iPS cell-related research reagents, collaborating with the University of Tokyo and Kyoto University. The company also offers contract manufacturing services.
Sector
Chemicals
ReproCELL Incorporated develops businesses centered on iPS cell-related technologies. In its research support division, the company manufactures and sells research products, provides research outsourcing services, and distributes cell measurement equipment. The medical division focuses on regenerative medicine research and development, contract manufacturing of iPS cell regenerative medicine products, and clinical testing services. Currently, ReproCELL is developing three regenerative medicine products: StemCaimal, iPS neural glial cells, and tumor-infiltrating lymphocyte infusion therapy. The company's strength lies in its RNA reprogramming technology, which enables the creation of highly safe iPS cells.